Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Average Rating of “Buy” from Analysts

Caribou Biosciences, Inc. (NASDAQ:CRBU) has been given a consensus recommendation of “Buy” by the five analysts that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.33.

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Bank of America dropped their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, Citigroup dropped their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th.

Caribou Biosciences Trading Down 5.5 %

Shares of Caribou Biosciences stock opened at $1.55 on Tuesday. The company’s 50-day moving average price is $2.00 and its two-hundred day moving average price is $2.00. Caribou Biosciences has a 52 week low of $1.50 and a 52 week high of $8.33. The stock has a market cap of $140.36 million, a PE ratio of -0.94 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. On average, equities analysts predict that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Erste Asset Management GmbH purchased a new position in Caribou Biosciences during the 3rd quarter valued at about $28,000. AQR Capital Management LLC purchased a new position in Caribou Biosciences during the 2nd quarter valued at about $30,000. China Universal Asset Management Co. Ltd. grew its stake in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after acquiring an additional 6,768 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Caribou Biosciences in the 3rd quarter valued at approximately $43,000. Finally, Point72 DIFC Ltd grew its stake in shares of Caribou Biosciences by 389.4% in the 2nd quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after buying an additional 23,995 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.